3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Imatinib Mesylate
26
Sunitinib
22
nilotinib
12
ripretinib
11
regorafenib
7
avapritinib
7
tanespimycin
2
pexidartinib
2
masitinib
2
famitinib
2
Midazolam
2
IDRX-42
2
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
2
umbralisib
1
trastuzumab deruxtecan
1
trametinib
1
tinostamustine
1
spartalizumab
1
ribociclib
1
repaglinide
1
ponatinib
1
perifosine
1
pembrolizumab
1
olverembatinib
1
olaratumab
1
motesanib diphosphate
1
dabrafenib
1
cediranib
1
binimetinib
1
anlotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Gastrointestinal Stromal Tumors
×
tinostamustine
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts